- Home
- DRMA vs SNTG Comparison
DRMA vs SNTG Comparison
Compare DRMA & SNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- SNTG
- Stock Information
- Founded
- DRMA 2014
- SNTG 2009
- Country
- DRMA United States
- SNTG China
- Employees
- DRMA N/A
- SNTG N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- SNTG Finance: Consumer Services
- Sector
- DRMA Health Care
- SNTG Finance
- Exchange
- DRMA Nasdaq
- SNTG Nasdaq
- Market Cap
- DRMA 4.5M
- SNTG 4.8M
- IPO Year
- DRMA 2021
- SNTG 2021
- Fundamental
- Price
- DRMA $0.60
- SNTG $1.84
- Analyst Decision
- DRMA Strong Buy
- SNTG
- Analyst Count
- DRMA 1
- SNTG 0
- Target Price
- DRMA $3.00
- SNTG N/A
- AVG Volume (30 Days)
- DRMA 94.5K
- SNTG 6.5K
- Earning Date
- DRMA 08-06-2025
- SNTG 07-07-2025
- Dividend Yield
- DRMA N/A
- SNTG N/A
- EPS Growth
- DRMA N/A
- SNTG N/A
- EPS
- DRMA N/A
- SNTG N/A
- Revenue
- DRMA N/A
- SNTG $107,507.00
- Revenue This Year
- DRMA N/A
- SNTG N/A
- Revenue Next Year
- DRMA N/A
- SNTG N/A
- P/E Ratio
- DRMA N/A
- SNTG N/A
- Revenue Growth
- DRMA N/A
- SNTG N/A
- 52 Week Low
- DRMA $0.57
- SNTG $1.43
- 52 Week High
- DRMA $5.00
- SNTG $3.97
- Technical
- Relative Strength Index (RSI)
- DRMA 29.24
- SNTG 54.53
- Support Level
- DRMA $0.57
- SNTG $1.67
- Resistance Level
- DRMA $0.63
- SNTG $1.92
- Average True Range (ATR)
- DRMA 0.04
- SNTG 0.09
- MACD
- DRMA -0.01
- SNTG 0.01
- Stochastic Oscillator
- DRMA 11.55
- SNTG 62.96
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.